Skip to content
Commercial Litigation Woods Lonergan LLP

212.684.2500

Copyright Litigation

Predictive Technology Group Finalizes Letter of Intent to Acquire ... - GlobeNewswire (press release)

January 9, 2018 - 1:04pm

Predictive Technology Group Finalizes Letter of Intent to Acquire ...
GlobeNewswire (press release)
SALT LAKE CITY, Utah, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK:PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through unique biotechnology treatments ...

and more »

Dogness to Attend CES 2018 Nasdaq:DOGZ - GlobeNewswire - GlobeNewswire (press release)

January 9, 2018 - 8:31am

Dogness to Attend CES 2018 Nasdaq:DOGZ - GlobeNewswire
GlobeNewswire (press release)
DONGGUAN, China, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Dogness (International) Corporation (NASDAQ:DOGZ)(“Dogness” or the “Company”), a leading developer and manufacturer of pet products, including leashes, accessories, and collars and harnesses that ...

and more »

XpresSpa Opens Off-Airport Prototype Location at Westfield World Trade Center - GlobeNewswire (press release)

January 9, 2018 - 8:31am

GlobeNewswire (press release)

XpresSpa Opens Off-Airport Prototype Location at Westfield World Trade Center
GlobeNewswire (press release)
The new XpresSpa location, situated in the World Trade Center's “Oculus” complex, offers an extensive menu of signature spa services such as Xpres massages, Xpres blowouts, Xpres manicures and Xpres facials, featuring products from its exclusive ...

and more »

Mid Penn Bancorp, Inc. completes merger with The Scottdale Bank ... - GlobeNewswire (press release)

January 9, 2018 - 8:15am

Mid Penn Bancorp, Inc. completes merger with The Scottdale Bank ...
GlobeNewswire (press release)
MILLERSBURG, Pa., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Mid Penn Bancorp, Inc. (“Mid Penn”) (NASDAQ:MPB) today announced that its merger with The Scottdale Bank & Trust Company was completed on January 8, 2018. Scottdale has been merged with and into Mid ...

and more »

MoneyTrac Technology, Inc. Teams Up with High Grade ... - GlobeNewswire (press release)

January 9, 2018 - 8:03am

MoneyTrac Technology, Inc. Teams Up with High Grade ...
GlobeNewswire (press release)
SAN DIEGO, Jan. 09, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Global Payout, Inc. (OTCPink:GOHE) ("Global") is pleased to announce that its majority owned subsidiary, MoneyTrac Technology, Inc. ("MTRAC" "MoneyTrac", the "Company") has executed a ...

and more »

IRIDEX Announces Infringement Lawsuit Against Quantel Nasdaq:IRIX - GlobeNewswire (press release)

January 9, 2018 - 7:05am

IRIDEX Announces Infringement Lawsuit Against Quantel Nasdaq:IRIX
GlobeNewswire (press release)
MOUNTAIN VIEW, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ:IRIX) announced today that it has filed a lawsuit against Quantel Medical, S.A., Quantel USA, Inc., and Quantel, S.A. in the U.S. District Court for the Northern ...

and more »

Ziopharm Oncology Provides Update on Standout Technologies during the 36th Annual JP Morgan Healthcare ... - GlobeNewswire (press release)

January 9, 2018 - 7:05am

Ziopharm Oncology Provides Update on Standout Technologies during the 36th Annual JP Morgan Healthcare ...
GlobeNewswire (press release)
... whether chimeric antigen receptor T cell (CAR-T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, and the Company's other therapeutic products it develops will be successfully marketed if approved; the strength and enforceability of the ...

and more »

Axsome Therapeutics Announces AXS-02 Independent Data ... - GlobeNewswire (press release)

January 9, 2018 - 7:05am

Axsome Therapeutics Announces AXS-02 Independent Data ...
GlobeNewswire (press release)
NEW YORK, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that an independent ...

and more »

Blackbird Energy Inc. Provides Initial Production Results From Its Condensate-Rich Pipestone/Elmworth Montney Play - GlobeNewswire (press release)

January 9, 2018 - 3:01am

Blackbird Energy Inc. Provides Initial Production Results From Its Condensate-Rich Pipestone/Elmworth Montney Play
GlobeNewswire (press release)
... the concentration of the Company's assets in the Pipestone / Elmworth Project area; unforeseen title defects; aboriginal claims; failure to accurately estimate abandonment and reclamation costs; development and exploratory drilling efforts and well ...

and more »

Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab** - GlobeNewswire (press release)

January 9, 2018 - 1:16am

Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**
GlobeNewswire (press release)
In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory ...

and more »

ASMI Share Buyback Update January 1-5, 2018 Amsterdam Stock ... - GlobeNewswire (press release)

January 8, 2018 - 11:46am

ASMI Share Buyback Update January 1-5, 2018 Amsterdam Stock ...
GlobeNewswire (press release)
ASM International N.V. (Euronext Amsterdam: ASM) reports the following transactions, conducted under ASMI's current share buyback program. Date, Repurchased shares, Average price, Repurchased value. January 2, 2018, 37,614, € 56.90, € 2,140,395 ...

and more »

FORM Holdings is Now XpresSpa Group, Inc. - GlobeNewswire (press release)

January 8, 2018 - 9:31am

FORM Holdings is Now XpresSpa Group, Inc.
GlobeNewswire (press release)
Our team has recruited top talent for corporate and field teams, accelerated unit growth, reinvested in marquee locations and extended leases, significantly streamlined operations and engaged in new exclusive partnerships that bring XpresSpa customers ...

and more »

RespireRx Pharmaceuticals Inc. to Present at 10th Annual Biotech ... - GlobeNewswire (press release)

January 8, 2018 - 8:45am

RespireRx Pharmaceuticals Inc. to Present at 10th Annual Biotech ...
GlobeNewswire (press release)
Glen Rock, N.J., Jan. 08, 2018 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC QB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for the treatment of respiratory disorders for which there are no approved ...

and more »

pSivida Submits New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis to the ... - GlobeNewswire (press release)

January 8, 2018 - 8:31am

pSivida Submits New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis to the ...
GlobeNewswire (press release)
... including our agreement with Alimera; termination or breach of current license agreements, including our agreement with Alimera; our dependence on contract research organizations, vendors and investigators; effects of competition and other ...

and more »

ARCA biopharma Announces Completion of GENETIC-AF Phase 2B ... - GlobeNewswire (press release)

January 8, 2018 - 8:31am

GlobeNewswire (press release)

ARCA biopharma Announces Completion of GENETIC-AF Phase 2B ...
GlobeNewswire (press release)
WESTMINSTER, Colo., Jan. 08, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced the ...

and more »

Gopher Protocol Year in Review -- Transition to Revenue Generating Company Equipped with $1M cash - GlobeNewswire (press release)

January 8, 2018 - 8:03am

Gopher Protocol Year in Review -- Transition to Revenue Generating Company Equipped with $1M cash
GlobeNewswire (press release)
Atlanta, GA, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Gopher Protocol Inc. (OTCQB: GOPH) ("Gopher"), a development-stage company which specializes in the creation of Internet of Things (IoT) and Artificial Intelligence enabled mobile technologies, releases a ...

Athenex Announces Chinese FDA Allowance of Investigational New Drug Application of Oraxol to Begin Clinical Trials - GlobeNewswire (press release)

January 8, 2018 - 8:03am

Athenex Announces Chinese FDA Allowance of Investigational New Drug Application of Oraxol to Begin Clinical Trials
GlobeNewswire (press release)
Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the development stage of our primary clinical candidates and ...

and more »

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

MoneyMakingArticles

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ...
GlobeNewswire (press release)
... risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability ...
Alder Biopharmaceuticals, Inc. - ALDR - Stock Price Today - ZacksZacks Investment Research

all 84 news articles »

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

MoneyMakingArticles

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ...
GlobeNewswire (press release)
... risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability ...
Alder Biopharmaceuticals, Inc. - ALDR - Stock Price Today - ZacksZacks Investment Research

all 84 news articles »

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

MoneyMakingArticles

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ...
GlobeNewswire (press release)
... risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability ...
Alder Biopharmaceuticals, Inc. - ALDR - Stock Price Today - ZacksZacks Investment Research

all 84 news articles »